<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306094</url>
  </required_header>
  <id_info>
    <org_study_id>NP1105/17</org_study_id>
    <nct_id>NCT04306094</nct_id>
  </id_info>
  <brief_title>Factors Determining the Prognosis in NSCLC Stage IV</brief_title>
  <acronym>LUPROG</acronym>
  <official_title>Predictive Prognostic Factors in Patients With Non-small Cell Lung Cancer Stage IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de S達o Paulo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a cohort study with patients with advanced NSCLC. Patients will answer&#xD;
      questionnaires about symptoms and quality of life and will be submitted to physical and blood&#xD;
      tests, and computer tomography. The aim of this study is to estimate prognostic factors&#xD;
      predicting survival to 3 months in patients with advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small-cell lung cancer (NSCLC) is currently the neoplasm leading in deaths worldwide and&#xD;
      in Brazil. NSCLC has a high incidence, is usually diagnosed in advanced stages and has poor&#xD;
      survival rates. The ability to refine the prognosis of a disease has implications at the time&#xD;
      of diagnosis and decision about treatment. Clinical and laboratory factors are studied to&#xD;
      evaluated the prognosis of diseases. Palliative Prognostic Score (PaP score), Karnofsky&#xD;
      Performance Status Scale (KPS), Palliative Prognostic Index (PPI) are applied in patients&#xD;
      with many types of solid tumors. The Charlson Score evaluates comorbidities and the&#xD;
      attributed risk for presence it. Others predictors of prognostic are cachexia, quality of&#xD;
      life, inflammatory factors, sarcopenia. There is a need to improve the ability to estimate&#xD;
      the prognosis and to identify the factors responsible to low survival rates in patients with&#xD;
      NSCLC diagnosed at advanced stage, also as a tool for a better treatment selection.&#xD;
&#xD;
      This is an observational and prospective study, including patients diagnosed with NSCLC and&#xD;
      admitted in ICESP, staged as IV at admission, with no previous systemic treatment and&#xD;
      classified as ECOG 2-4. Demographic data, presence of a caregiver, anthropometry, MRC dyspnea&#xD;
      scale, KPS, Edmont Symptom Scale, Charlson's Comorbidity Score, PPI and PaP were evaluated in&#xD;
      each patient. Evaluation of sarcopenia and cachexia with abdominal CT (Slice-O-Matic, v.5),&#xD;
      arm circumference, handgrip strength test and quality of life using EORTC score QLQ C-30 and&#xD;
      QLQ-CAX-24 were also evaluated. Significant prognostic factors will be selected by&#xD;
      multivariate analysis in a training set estimated as 217 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 months</time_frame>
    <description>to assess overall survival in patients with NSCLC</description>
  </primary_outcome>
  <enrollment type="Anticipated">217</enrollment>
  <condition>NSCLC Stage IV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC patient, treatment naive with Eastern Cooperative Oncology Group Performance status&#xD;
        2-4 (ECOG PS).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced stage IVa or IVb NSCLC patients histologically diagnosis.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance status 2 - 4&#xD;
&#xD;
          -  Treatment-naive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initiate treatment before initiate&#xD;
&#xD;
          -  psychiatric illnesses, except depression&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  two concomitant neoplasms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ana p borges</last_name>
    <phone>+5511969057406</phone>
    <email>aninhapsb@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ana Paula de Souza Borges</name>
      <address>
        <city>S達o Paulo</city>
        <zip>04513100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ana p borges</last_name>
      <phone>11969057406</phone>
      <email>aninhapsb@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Cancer do Estado de S達o Paulo</investigator_affiliation>
    <investigator_full_name>Ana Paula de Souza Borges</investigator_full_name>
    <investigator_title>physician, MD</investigator_title>
  </responsible_party>
  <keyword>prognostic factor</keyword>
  <keyword>survival</keyword>
  <keyword>lung cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

